ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

guselkumab

Also written as “Guselkumab”, “Guselkumab Dose 1” and “Guselkumab Dose 2”.

Its studies are mostly in Psoriasis · Crohn Disease · Arthritis, Psoriatic · Colitis, Ulcerative · Arthritis, Juvenile, led by 3 companies.

Drug pageGuselkumab: every studyAll 80 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 3, 202160 company-led studies, 19 open or runningNext primary completion: Nov 20, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only5818 open or runningphase 4since Jun 3, 2021Sep 2, 2011Feb 10, 2027phase 3 · NCT06260163
Eli Lillyits history only10 open or runningphase 4since Jun 20, 2018Jun 20, 2018none ahead
Surmount Services11 open or runningphase 1since Aug 20, 2026Aug 20, 2026Nov 20, 2026phase 1 · NCT07788807

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Surmount Services only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 20, 2026First study: phase 1 study in Healthy SubjectsFirst studyNCT07788807 · 18 planned · Australia

Ahead

  1. Nov 20, 2026Primary completion: phase 1 study in Healthy SubjectsNCT07788807

TargetBeta

IL12B →IL23A →read by rule
“Interleukin-23 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
risankizumabruleAbbViephase 468
mirikizumabruleEli Lillyphase 436

Studies

The one study Surmount Services leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07788807Healthy Subjects · Australia1RecruitingNov 20, 202618

How it is read

Names in the registry

  • “Guselkumab”, 43 entries
  • “Guselkumab Dose 1”, 7 entries
  • “Guselkumab Dose 2”, 7 entries
  • “Guselkumab Dose 3”, 4 entries
  • “Guselkumab 100 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.